Areteia Therapeutics
Clinical-stage biopharmaceutical company developing novel therapies for severe respiratory diseases, including eosinophilic asthma and other inflammatory conditions.
Notes
Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for severe respiratory diseases. The company was formed to develop RVT-1601 (now known as ART-1601), an inhaled anti-thymic stromal lymphopoietin (TSLP) antibody for the treatment of severe eosinophilic asthma and other respiratory inflammatory diseases.
The company's approach targets the upstream inflammatory pathways involved in asthma and other respiratory conditions. By targeting TSLP, a key epithelial cytokine, Areteia aims to address the root causes of airway inflammation rather than just treating symptoms.
Areteia Therapeutics was launched with backing from Bain Capital Life Sciences and other investors to develop respiratory therapeutics with differentiated mechanisms of action.
Team
- Lars Bjerrum, Ph.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/lars-bjerrum
- Gina Eagle - Chief Medical Officer
- Andrew Bhagwagar, M.D. - Board Member
Additional Research Findings
- Backed by Bain Capital Life Sciences
- Lead program ART-1601 (anti-TSLP antibody) for severe eosinophilic asthma
- Inhaled biologic approach for respiratory diseases
- Focus on upstream inflammatory pathways
- Boston, Massachusetts headquarters
- Clinical-stage company
- Founded 2021